- Home
- BTMD
BTMD
Biote Corp.
as 05-20-2024 12:33pm EST
$.
-
$.
-.%
Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.
| Founded: | 2012 | Country: | United States |
| Employees: | N/A | City: | IRVING |
| Market Cap: | 177.1M | IPO Year: | N/A |
| Target Price: | $8.11 | AVG Volume (30 days): | 115.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 5 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.25 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.65 - $8.22 | Next Earning Date: | 05-07-2024 |
| Revenue: | $187,321,000 | Revenue Growth: | 8.49% |
| Revenue Growth (this year): | 11% | Revenue Growth (next year): | 15.88% |
Share on Social Networks:
Latest Biote Corp. News
BTMD Breaking Stock News: Dive into BTMD Ticker-Specific Updates for Smart Investing
Insider Monkey
11 days ago
biote Corp. (PNK:BTMD) Q1 2024 Earnings Call Transcript
Thomson Reuters StreetEvents
12 days ago
Q1 2024 Biote Corp Earnings Call
Zacks
13 days ago
Biote Corp. (BTMD) Q1 Earnings Beat Estimates
GuruFocus.com
13 days ago
Biote Corp (BTMD) Q1 2024 Earnings: Performance Aligns with Analyst Revenue Projections
Business Wire
13 days ago
Biote Reports First Quarter 2024 Financial Results
Zacks
20 days ago
Earnings Preview: biote Corp. (BTMD) Q1 Earnings Expected to Decline
Business Wire
21 days ago
Biote Announces Definitive Settlement with Founder
Business Wire
a month ago